AstraZeneca Plc and Bristol-Myers Squibb Co. urged a Philadelphia federal appeals court not to revive a 10-year-old lawsuit alleging the drugmakers paid kickbacks to benefits manager Medco Health Solutions Inc.
Novo Nordisk A/S, the world’s biggest insulin maker, is seeing a rebound in sales of its Victoza diabetes treatment in the U.S. after a few months of flat growth, Chief Financial Officer Jesper Brandgaard said.
U.S. stocks rose, sending the Standard & Poor’s 500 Index to a record, as Amazon.com Inc. and Microsoft Corp. sales beat estimates while a drop in consumer confidence added to speculation the Federal Reserve will delay scaling back monetary stimulus.
More than half of senior citizens surveyed mistakenly attributed rising costs of their medicines to Obamacare, according to Express Scripts Holding Co., a misunderstanding that is contributing to the law’s unpopularity.
Novo Nordisk A/S, the world’s biggest insulin maker, isn’t on a downward trajectory and moved forward on many projects this year following a setback to its most promising product, its chief scientist said.
Eli Lilly & Co. is counting on the quality of a diversified product portfolio over boosting its sales forces to grab a bigger slice of the $22 billion U.S. diabetes market, a difference in strategy to some of its rivals.